Clinical Trials · NCT01206101
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 3
- Start date
- Mar 2012
- Locations
- 16 sites, 6 countries
- Primary endpoint
- Proportion Of Insulin-independent Subjects After Receiving Only One (Single-Donor) Islet Cell Transplant